Introduction
The etiology of fetal bradycardia following paracervical block (PCB) is not clear. Vasoconstriction of the uterine arteries, hypertonus of the uterus, and the direct toxic effect of a local anesthetic agent on the fetus or a combination of the above have been presented as etiological factors [17] . To reduce fetal side-effects, a superficial and low dosage technique has been advised by BLOOM [2] and JÄGERHORN [10] . By this method it may be possible to decrease the rate of the absorption of an anesthetic agent from the highly vascular paracervical space. Since there is no consistent information about the maternal and fetal effects of this kind of PCB, we have studied the fetal heart rate patterns (FHR), uterine activity, placental blood flow, and fetal acid-base balance in connection with such a block. In addition, we measured the actual maternal, fetal and neonatal plasma bupivacaine levels.
2 Materials and methods 2.1 Patients: Thirty-eight patients, who had an uncomplicated pregnancy, were between the 39-41 weeks of gestation and in active labor with the fetus in cephalic presentation were studied. In three cases a second PCB was used approximately two hours after the first block, so the material number includes in total 41 PCBs. patients varied from 18 to 28 years (mean ± SD, 24.3 ± 3.7), and the parity from 1 to 3 (1.6 ± 0.5). The mean duration of the labor was 10 hours 52 minutes ± 3 hours 37 minutes and the mean period from PCB to delivery 2 hours 24 minutes ± 1 hour 19 minutes. The mean weight of the babies was 3,565 ± 352 grams and all but one had APGAR scores of 8 or better at 1,5 and 15 minutes. The one exception was a baby who had 3/6/8 scores at 1,5 and 15 minutes and was delivered by vacuum extraction because of bradycardia in the second stage of labor, 4 hours 32 minutes after PCB. Another baby was also delivered by vacuum extraction due to prolongation of the second stage 2 hours and 12 minutes after PCB but was in excellent condition after delivery. One cesarean section was performed 8 hours after PCB because of persistent occiput posterior presentation.
Paracervical block:
The block was performed when the patient had painful contractions and the cervix was dilated 4 to 7 cm. During the procedure the patient was in the left lateral (tilted 30°) position, and after PCB she was turned into a totally lateral position. During and 30 minutes after the procedure, the patient received 500 ml of RINGER solution. The patient's heart rate and blood pressure were recorded before the PCB and at three minutes intervals during the first 30 minutes after the block. Bupivacaine with a total dose of 10 ml (25 mg) of 0.25 % solution was used. Five ml of the solution was injected with a KOBAK's needle to each lateral fornix and the depth of the injection was limited to no more than 3mm.
2.3 Fetal heart rate (FHR) monitoring: At least 30 minutes before PCB the membranes were ruptured if not already ruptured, and the FHR of the fetuses were directly monitored using a scalp electrode during a control period of at least 20 minutes before PCB and thereafter until delivery. The details of the FHR pattern were analyzed visually. The decelerations were classified according to HON [7] . Baseline variability was evaluated by the maximum amplitudes for 1-minutes periods. An amplitude less than 5 beats per minute for more than 5 minutes was regarded as being of the silent type. Acceleration was defined as an increase of FHR from baseline by more than 15 beats in less than 30 seconds. Bradycardia was defined as a decrease of mean FHR of at least 20 bpm or an absolute rate less then 100 bpm and of a duration greater than two minutes. Baseline, baseline variability, the number of different decelerations (early, late, variable), accelerations and the occurrence and duration of bradycardia were determined for each ΙΟ-minute period during the 20 minute prior PCB and 30 minute after the block.
Uterine activity:
In eleven patients the intrauterine pressure was measured using an openended transcervical intrauterine catheter connected to a strain gauge placed at the level of the sternum. In these patients the baseline uterine tone, frequency, and amplitude of contractions (measured in MONTEVIDEO units) were recorded during a 20 minute control period and 30 minute observation period after PCB. In other patients frequency and relative change in amplitude of contractions were measured by external tocography.
2.5 Placental blood flow: Both intervillous and myometrial blood flow was measured in ten patients with the placenta at the anterior wall of the uterus just before and 10 minutes after PCB. These patients remained in the tilted left laterally position from PCB until the second measurement. The placental blood flow in ml/min/100 ml of the intervillous space was measured by 133 Xe-washout method described in detail elsewhere [15] .
2.6 Bubivacaine concentrations: Blood samples for the determination of the plasma bupivacaine concentration were taken from a maternal vein and the fetal scalp 20 minutes after PCB and at delivery from a maternal vein and the umbilical artery and vein. The plasma bupivacaine concentrations were measured with a specific gas-liquidchromatographic method [11] .
2.7 Fetal acid-base balance: A fetal scalp sample and umbilical venous and arterial blood samples were obtained in 14 cases. The actual pH was immediately determined according to the method of S AUNG just before the. PCB and 15 to 20 minutes after PCB and at delivery.
Statistics:
STUDENT'S t-test and Chi-Squaretest were used for the statistical analyses of the results.
Results

Maternal effects:
The analgesic effect of a single PCB as assessed by the patients was good in 31 cases (76%), "moderately good" in 5 cases (12%), and "poor" in 5 cases (12%). The duration of the PCB varied from one to two hours. The maternal heart rate was 80 ± 11 bpm before and 85 ± 7 after the PCB on average. Systolic blood pressure was correspondingly 131 ±21 mmHg and 3.2 Fetal heart rate pattern: The results are summarized in Tab. I The mean basal fetal heart rate during the 10 minute periods did not change significantly. The baseline fetal heart rate variability decreased significantly during the period from 10 minutes through 20 minutes after PCB. Recordings without FHR accelerations were noticed only once during the control period but 11 times (27 %) (p < 0.001) during the second and 6 times (15%) (p < 0.01) during the third observation period after PCB. Bradycardia was not observed during the control period but appeared in 12% of the cases (p<0.01) after PCB. One case demonstrating fetal bradycardia is presented in Fig. 1 . Fetal heart rate decelerations of early or variable type more than 30 bpm appeared significantly (p < 0.05) more often during the first observation period than during the control time. Late decelerations (4 and 5 during the first and second observation periods, respectively) occurred only after PCB. No cases of silent pattern were noticed during the control period but appeared in 20 % of the cases after the block (p < 0.05).
Bupivacaine concentrations:
Mean maternal bupivacaine concentration 20 minutes after PCB was 0.14±0.06ug/ml and 0.07 ± 0.04 at birth. Simultaneous fetal, umbilical venous and arterial concentrations were correspondingly 0.04 ±0.02, 0.03 ± 0.01 and 0.03 ± 0.01 ug/ml and they were significantly (p < 0.001) lower than the respective maternal concentrations. Individual maternal and fetal concentrations and their changes at 20 minutes after PCB and at delivery are shown in Figs. 2, 3 and 4. One episode of bradycardia occurred in these eleven cases (indicated in Fig.4 ). 3.5 Uterine activity: No significant changes in uterine tone, amplitude and frequency of contractions were observed after PCB. Mean Montevideo units were 155 ± 12 before and 150 ±20, 152 ±12, 165 ± 15 during the three ten minute-periods after PCB (p > 0.05). An obvious hypertonus of the uterus after PCB was observed in three cgses of bradycardia but not in the other two cases of bradycardia, in the eight cases of silent FHR pattern or in nine cases of late decelerations. PCB (p > 0.05). Individual fetal scalp pH values as well as mean umbilical arterial values (2 hours 20 minutes after PCB) are shown in Fig. 6 . In three cases of bradycardia the mean fetal pH was 7.28 after PCB. Mean pH from umbilical venous blood was 7.27 ± 0.08 and arterial blood 7.36 ±0.09.
Discussion
In spite of extensive clinical experience and research work, the usefulness and safety of PCB is still a matter of controversy [9, 17] . To reduce fetal hazards, a low dosage, superficial technique of PCB has been advised by BLOOM [2] and by JÄGERHORN [10] and was also used in our study. The success rate (76%) and the failure rate (12%) we found using that technique are of a similar order to that reported when using larger bupivacaine dosages [17] . The plasma levels of bupivacaine after low dosage (25 mg) administration in maternal, fetal and neonatal blood are lower than reported by HYMAN [8] (maternal 0.14, neonatal 0.08ug/ml) or by BEAZLEY [1] (1.07 and 0.10), who used 50 mg of bupivacaine at PCB. No results of plasma bupivacaine concentration in connection with the present low dosage PCB have been published. On the other hand, in connection with epidural analgesia using 25 mg of bupivacaine correspondingly low levels have been observed [11] . The maternal-fetal ratios of bupivacaine after PCB or at delivery are in our results very similar to earlier studies using bupivacaine in PCB [1, 8] or in epidural blocks [11] . Thus, it thus seems possible to decrease fetal and maternal levels of bupivacaine by using a low dosage and by superficial injection technique without loss of any of the analgesic effect. Despite reduced fetal bupivacaine levels, several significant changes in the FHR occurred after PCB in the present series. In the whole group about one-third of the blocks were associated with noticeable changes. Our results do not agree with some earlier studies reporting lack of FHR changes after low dosage PCB [10, 12, 14] . Bradycardia lasting on average for 8 minutes and starting 2-4 minutes after PCB was observed at a 12% rate. TERAMO [16] , by using 100mg or 50 mg of bupivacaine, found a 21 % frequency of bradycardia, HOLLMEN [6] a rate of 30%, JÄGERHORN [10] a 10% rate but MEIS [12] and REID [14] almost none. Comparison of FHR patterns after PCB are difficult because most earlier studies have not been done with direct FHR recording and also the criteria of pathological and non-pathological FHR patterns, e.g. bradycardia are not unambiguous. Late decelerations in our study were observed in five cases after PCB and mostly in association with bradycardia as also noted in earlier reports [16] . Decreased FHR variability (silent pattern) was > observed after 20% of the blocks which corre-|j sponds to the findings of MEIS et al. [12] . The ·! most frequent change in FHR after PCB in our | material was the disappearance of FHR accelera-i tions. The accelerations have been regarded as a sensitive sign of fetal arousal level and nonhypoxic state [7, 13] . Similar finding was also reported by MEIS [12] . The fetal pH did not decrease on average after j PCB but the fall was more pronounced in 3 cases with bradycardia which is in accordance with the findings of previous studies [16] . No universal change in the mean uterine activity was noticed after PCB, but in five cases demonstrating bradycardia three showed a prompt increase in uterine contractions and in the baseline tone, which might at least partly explain the change in the FHR pattern. The etiopathology of FHR "changes in connection with PCB is obviously multifactorial [17] . According to our observations the most important factor in these mechanisms seems to be the rapid transplacental passage of the local anesthetic agent into the fetal circulation. Since we were not able to show any decrease in placental blood flow after PCB even in cases of fetal bradycardia, the initial bradycardia obviously represents a direct toxic effect of bupivacaine on the fetal heart and on its regulatory centers. In vitro experiments using uterine artery pieces show [3, 4] that lidocaine can constrict these vessels for a considerable time, when much higher concentrations (400-1000 ug/ml) than seen in clinical practice are used. Extrapolation of these results in vivo conditions seems to be hardly applicable to human studies. In ewes a direct injection of bupivacaine into the maternal aorta bringing about a plasma concentration of 5 ug/ml results in hypertonus of the uterus, fetal bradycardia and decreased uterine blood flow [5] . These plasma concentrations are very high and in the interpretation of these animal studies it is difficult to determine which of the parameters is the primary one. Disappearance of FHR accelerations and decrease of FHR variability observed in our study represent a direct pharmacological effect of bupivacaine at fetal level. These kinds of changes are commonly seen after administration of many other drugs used in labor, e.g. pethidin (meperidine) [13] . Although there is obviously some relation between pathological FHR and fetal plasma concentration of the agent, the most important factor may still be the pharmacokinetic properties of the anesthetic agent, i.e. the rate of the rise of fetal drug concentration after the block. Our universal observation was that mothers with fetal bradycardia very rapidly achieved analgesia after PCB. The superficial injection technique was initially developed to reduce rapid absorption of the local anesthetic agent from the paracervical space. It seems possible that even after carefully applied blocks a rapid absorption of the drug may sometimes occur leading to an abrupt rise in blood concentrations and to fetal FHR changes. This observation may signify that the technique of PCB must be individually modified. Probably the best method to avoid rapid absorption is according to our recent experience, to maintain an interval of 10-15 minutes between the application of anesthetic solution to each side of the cervix.
Summary
Vasoconstriction of the uterine arteries, hypertonus of the uterus, and the direct toxic effects of a local anesthetic on the fetus or a combination of the above have been presented as etiological factors of fetal bradycardia following paracervical block. The reduce fetal sideeffects a superficial and lowdosage technique of PCB have been advocated. We have studied the effects of 25 mg of bupivacaine PCB using the above technique on fetal heart rate pattern (FHR), fetal acid-base balance, uterine activity, placental blood flow and maternal and fetal plasma levels of bupivacaine in 38 patients. The analgesic effect of a single 25 mg of bupivacaine PCB was good in 76 %, moderate in 12% and poor in 12% of the cases. No changes in maternal heart rate or in blood pressure were noted. Fetal bradycardia defined as a decrease of mean fetal heart rate of at least 20 bpm or an absolute rate less than 100 bpm and a duration greater than two minutes occurred in 12 % of the cases. The mean amplitude of the baseline fetal heart rate variability decreased significantly after PCB and a silent pattern (an amplitude less than 5 bpm) was observed in 20 % of the cases. The most frequent (27%) pathological finding in our study was the disappearance of FHR accelerations after PCB. Similarly early and late decelerations of FHR occurred more often after PCB than during the control period before the block. The fetal pH from scalp blood samples did not, on avarage, decrease after PCB, but did so in cases with fetal bradycardia. Intervillous blood flow as measured by the 133 Xe washout method did not change when measured before and after PCB. In addition in three cases with fetal bradycardia the changes in the intervillous blood flow were minimal. No significant changes in the mean uterine tone, amplitude and frequency of contractions were observed after PCB. However, an obvious uterine hypertonus was observed after PCB was observed in three cases of fetal bradycardia but not in two other cases of bradycardia or in the 8 cases of silent FHR pattern. Mean maternal bupivacaine concentration 20 minutes after PCB was 0.14 ± 0.06 ug/ml and 0.07 ± 0.04 ug/ml at birth. Simultaneous fetal and umbilical venous and arterial concentrations were correspondingly 0.04 ±0.02 ug/ml, 0.03 ± 0.01 ug/ml and 0.03 ± 0.01 ug/ml, and they were significantly lower than respective maternal concentrations. It seems possible to decrease fetal and maternal levels of bupivacaine by using a low dosage and superficial injection technique without loosing anything of the analgesic effect. However, several significant changes in fetal heart rate pattern can occur. About one third of the block were associated with noticable FHR changes in the present series. The etiopathology of FHR changes in connection with PCB is obviously multifactorial. According to our observations the most important factor in these mechanisms seems to be the rapid transplacental passage of the local anesthetic into fetal circulation. Since we were not able to show any decrease of placental blood flow after PCB even in cases with fetal bradycardia, the initial bradycardia obviously represents a direct toxic effect of bupivacaine on the regulatory centers of the fetal heart rate. Disappearance of FHR accelerations and the decrease of FHR variability observed in our study represent a pharmacological effect of bupivacaine at fetal level. In some cases uterine hypertonus following PCB may be an additional etiological factor of fetal bradycardia. It seems possible that even after carefully applied PCBs a rapid absorption of the local anesthetic agent may sometimes occur leading to an abrupt rise in the fetal blood concentrations and to fetal heart rate changes.
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Activite uterine, bloc para-cervical, bupivacaine, debit sanguin placentaire, pH foetal, rythme cardiaque foetal, taux plasmatiques de bupivacaine.
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